In a report released today, Daniel Brennan from TD Cowen maintained a Buy rating on NeoGenomics (NEO – Research Report), with a price target of $19.00.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Daniel Brennan has given his Buy rating due to a combination of factors influencing NeoGenomics’s future prospects. Despite a rare quarterly shortfall and the transition of the CEO leading to a sharp drop in the stock price, Brennan maintains a favorable long-term outlook. He believes the market reaction was overdone, especially considering the solid performance in the Clinical segment and a robust guidance provided by the company.
Another key consideration in Brennan’s rating is the anticipated recovery in the Pharma segment, which, although it underperformed in the fourth quarter, is expected to grow in the coming years due to strategic investments. The impending leadership of new CEO Tony Zook, with his strong background in pharma, is also seen as a positive factor. Furthermore, the company’s plans to expand its clinical sales force and launch new products are likely to drive growth, supporting Brennan’s optimistic stance on NeoGenomics.